Abstract
Systemic therapy of head and neck squamous cell carcinoma (HNSCC), in contrast to local therapy, is avery general term for the use of drugs that affect the entire organism. Immunotherapy is asubtype of systemic therapy, although the boundaries are hard to define, since the immune system is likely to play an essential role in all treatments. This article focuses on systemic therapy. All abstracts and presentations on systemic therapy of HNSCC from the American Society of Clinical Oncology (ASCO) 2024 annual congress were assessed for relevance. The main contributions were reviewed and summarized. For the first time, arandomized trial demonstrated asurvival advantage for systemic therapy in patients with apoor performance status over best supportive care (BSC). Clinical studies using antibody-drug conjugates (ADCs) show apromising response. In addition, the neoadjuvant approach was resumed through various study approaches. Even in patients with areduced general condition, systemic therapy can lead to asubstantial improvement in overall survival. The systemic therapy approach remains exciting for HNSCC, with new substances and areas of application not only in the palliative situation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
